8-K: Alumis Reports Q3 2026 Results, Psoriasis Drug Shows Promise

Alumis Inc. announced third quarter 2026 financial results, highlighting positive Phase 3 data for envudeucitinib in plaque psoriasis and mixed results for its lupus trial.

Summary

• Alumis Inc. reported its financial results for the quarter ended September 30, 2026.
• The company highlighted new Phase 3 data for envudeucitinib in plaque psoriasis, showing rapid and durable improvements, including a 54% PASI 100 response rate at Week 48.
• The New Drug Application (NDA) submission for envudeucitinib in plaque psoriasis is on track for the fourth quarter of 2026.
• Results from the Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus (SLE) did not meet primary endpoints in the overall population but showed robust responses in a prespecified subgroup of patients with high interferon gene signature (IFNGS-high).
• Alumis plans to initiate a Phase 2 biomarker trial for A-005, a CNS penetrant TYK2 inhibitor, in Parkinson's disease in 2027.
• As of September 30, 2026, the company had $431.3 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into the fourth quarter of 2027.
• Collaboration revenue was $1.9 million for the quarter, down from $2.1 million in the prior year.
• Net loss for the quarter was $94.9 million, an improvement from a net loss of $110.8 million in the same period last year.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with strong progress in plaque psoriasis offset by mixed results in lupus.

Positives

• New Phase 3 data for envudeucitinib in plaque psoriasis demonstrated rapid and durable improvements, with a 54% PASI 100 response rate at Week 48.
• High rates of scalp clearance (over 80% maintained clear/almost clear scalp at 48 weeks) and sustained itch relief (nearly 80% sustained clinically meaningful reduction through Week 48) were observed in the ONWARD3 trial.
• Early and durable quality-of-life improvements were noted, with over 70% of patients maintaining minimal to no impact of psoriasis on daily activities at 48 weeks.
• The NDA submission for envudeucitinib in plaque psoriasis remains on track for Q4 2026.
• Robust clinical responses were observed in the IFNGS-high subgroup for the SLE trial, indicating potential in a specific patient population.
• The company has a strong cash position of $431.3 million, providing runway into Q4 2027.
• Net loss improved to $94.9 million from $110.8 million year-over-year.
• A-005, a CNS penetrant TYK2 inhibitor, showed ability to penetrate the CNS in a Phase 1 study and is planned for a Phase 2 trial in Parkinson's disease in 2027.

Negatives

• The Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial population.
• Collaboration revenue decreased slightly to $1.9 million from $2.1 million in the prior year's quarter.
• Research and development expenses were $80.8 million, though this was a decrease from $97.8 million in the prior year, it reflects ongoing significant investment.

Risks

• The company faces risks related to regulatory approval, including whether regulatory authorities will accept the NDA submission and determine envudeucitinib has an acceptable safety and efficacy profile.
• There is uncertainty regarding the timing and results of clinical trials.
• Alumis's ability to obtain regulatory approval and commercialize its product candidates is subject to risk.
• Changes in operating plans and capital requirements could reduce the anticipated cash runway.
• The company may need to obtain additional funding to continue as a going concern.
• Risks associated with obtaining, maintaining, and enforcing intellectual property protection for its programs and product candidates.
• The LUMUS trial's failure to meet primary endpoints in the overall SLE population presents a significant hurdle for that indication.
• The IFNGS-high subgroup in SLE was unexpectedly under-represented in the LUMUS trial, impacting overall response rates.

Future Outlook

Alumis anticipates submitting its New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026. The company expects its current cash, cash equivalents, and marketable securities to fund operations into the fourth quarter of 2027. A Phase 2 biomarker trial for A-005 in Parkinson's disease is planned for 2027.

Management Comments

• "Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinibs highly competitive profile in moderate-to-severe plaque psoriasis," said Martin Babler, President and Chief Executive Officer of Alumis.
• "The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment."
• "Our fourth-quarter 2026 NDA submission remains on track."

Industry Context

StockSavvy.ai notes that Alumis is operating in the competitive biopharmaceutical space for immune-mediated diseases. The positive plaque psoriasis data positions envudeucitinib as a potential contender among oral therapies, while the mixed results in SLE highlight the challenges of developing treatments for complex autoimmune conditions and the importance of patient stratification.

Stakeholder Impact

• Shareholders: Positive outlook for plaque psoriasis drug development may increase shareholder value, while SLE trial results introduce uncertainty. Strong cash position provides operational stability.
• Patients: Potential for a new, effective oral therapy for plaque psoriasis. For SLE patients, the drug shows promise in a specific subgroup, but broader efficacy is yet to be confirmed.
• Employees: Continued investment in R&D and potential for future product launches supports employment. Launch preparation activities may increase workload.
• Creditors: The company's cash runway into late 2027 suggests short-term solvency, reducing immediate risk to creditors.

Next Steps

• Submit NDA for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026.
• Obtain two-year safety data for envudeucitinib in plaque psoriasis in Q4 2026.
• Conduct end-of-Phase 2 regulatory interactions for envudeucitinib in SLE.
• Evaluate development options for envudeucitinib in SLE.
• Initiate a Phase 2 biomarker trial for A-005 in Parkinson's disease in 2027.

Key Dates

Recommendation

The company shows strong progress in its lead indication (plaque psoriasis) with an upcoming NDA submission and positive clinical data. However, the failure of the SLE trial in the overall population introduces significant risk and uncertainty for that program. The robust cash position is a positive, but the mixed clinical outcomes warrant a 'hold' rating pending further clarity on the SLE development path and regulatory feedback.

Keywords

envudeucitinib, plaque psoriasis, systemic lupus erythematosus, TYK2 inhibitor, biopharmaceutical, clinical trial, NDA submission, Parkinson's disease